文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET/CT在生化应答期提前检出转移性前列腺癌复发

Early Detection of Metastatic Prostate Cancer Relapse on 68Ga-PSMA-11 PET/CT in a Patient Still Exhibiting Biochemical Response.
PubMed 文献 · Clin Nucl Med · 2020-01-01

本文报道一例激素敏感性转移性前列腺癌患者在接受多西他赛后、PSA仍显示生化应答时,68Ga-PSMA-11 PET/CT即检出早期复发。提示PSMA PET/CT可用于监测化疗反应,不受PSA水平限制,有助于发现低体积寡进展病变。

要点

  • PSA生化应答期间仍可能出现PSMA PET/CT可见的早期复发。
  • PSMA PET/CT监测化疗反应可早于生化进展发现复发。
  • 有助于识别低体积寡进展病变,为后续治疗决策提供依据。

核心结论

  • PSMA PET/CT可在PSA生化进展之前检出转移性前列腺癌的早期复发,应考虑用于监测化疗反应。

研究设计与样本

  • 本文为个案报道,描述一例接受多西他赛治疗的激素敏感性转移性前列腺癌患者的诊疗经过。

主要发现

  • 该患者在仍处于生化应答、尚未出现生化进展时,68Ga-PSMA-11 PET/CT已检出疾病复发。

临床怎么用

  • 对接受化疗的转移性前列腺癌患者,可考虑用PSMA PET/CT监测反应,不必仅依赖PSA水平判断复发。
  • PSMA PET/CT早期检出复发有助于发现低体积寡进展病变,从而增加局部或寡转移定向治疗的机会。

局限性

  • 本文为单一病例报道,结论的外推需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer (PCa) treatment monitoring usually relies on prostate-specific antigen to detect disease progression or relapse. PET/CT with prostate-specific membrane antigen (PSMA) ligands has shown high accuracy in detecting metastatic PCa lesions and could help assess response to therapy. We describe herein the early relapse detection of a hormone-sensitive metastatic upfront PCa treated with docetaxel on Ga-PSMA-11 PET/CT before biochemical progression. PSMA PET/CT should be considered to monitor PCa response to chemotherapy to detect early relapse, regardless of prostate-specific antigen levels, increasing the chances of finding low-volume oligoprogressive disease.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Plouznikoff N, Artigas C, Sideris S, et al. Early Detection of Metastatic Prostate Cancer Relapse on 68Ga-PSMA-11 PET/CT in a Patient Still Exhibiting Biochemical Response. Clin Nucl Med. 2020. PMID: 31693605. doi:10.1097/RLU.0000000000002799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。